The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer

Wigmore, Stephen J.; Ross, James A.; Falconer, John; Plester, C.E.; Tisdale, Michael J.; Carter, David C.; Fearon, K. C. H.

doi:10.1016/0899-9007(95)00078-x

Cited by 276 publications

(89 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The concentration of DHA in phospholipids increased in most studies after supplementation of EPA and DHA (4,20,44,45,47,48,50,51,54,55,60). Two studies reported unchanged plasma phospholipids concentrations of DHA after supplementation of EPA and DHA (24,57).…”

Section: Oral or Enteral Supplementation Of N23 Fasmentioning

confidence: 93%

“…Studies showed variable increases of plasma n23 FAs after supplementation of 0.5-6.9 g EPA and 0.2-3.6 g DHA during variable periods as follows: short-term [4 d (23), 7 d (23, 24), and 2 wk (55,65), respectively] and long-term [2-6 mo (42, 44, 45, 48,50,53,57)] supplementation of n23 FAs. In a few doseescalation studies, a plateau of the maximal incorporation into plasma phospholipids was reached at doses .2 g EPA; 2.1 g EPA (46) and 2.8-4.2 g EPA (41) did not further increase plasma EPA concentrations after 15 d and 6 mo, respectively.…”

Section: Oral or Enteral Supplementation Of N23 Fasmentioning

confidence: 99%

“…In total, we n23 PUFAs IN CANCER, SURGERY, AND CRITICAL CARE retrieved 23 RCTs and 13 open-label studies that reported incorporation or washout in cancer, surgery, and critical care after supplementation of n23 FAs via fish-oil capsules (7,(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59), ONSs (4,17,20,26,60), and/or enteral nutrition (23,24,26), or n23 FA lipid emulsions for parenteral administration (27,32,33,37,40,(61)(62)(63)(64) (see Supplemental Tables 1-3 under ''Supplemental data'' in the online issue). The following paragraphs summarize the most important findings.…”

Section: Incorporation and Washout Of N23 Fas After Supplementationmentioning

confidence: 99%

See 2 more Smart Citations

n–3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation

Meij

Schueren

Langius

et al. 2011

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

show abstract

Section: Oral or Enteral Supplementation Of N23 Fasmentioning

confidence: 93%

Section: Oral or Enteral Supplementation Of N23 Fasmentioning

confidence: 99%

Section: Incorporation and Washout Of N23 Fas After Supplementationmentioning

confidence: 99%

See 1 more Smart Citation

n–3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation

Meij

Schueren

Langius

et al. 2011

The American Journal of Clinical Nutrition

View full text Add to dashboard Cite

show abstract

“…Research on EPA has also suggested its ability to inhibit the downstream efects of LMF and PIF [134][135][136]. In past studies involving patients with unresectable pancreatic cancer, ish oil supplementation containing both EPA and DHA as well as highpurity EPA administration have both been associated with weight stabilization [137,138]. A study conducted by Barber et al further demonstrated the eicacy of EPA, which were taken through oral supplementation, at producing signiicant increases in weight, dietary intake, and performance status in cachectic patients with advanced pancreatic cancer [100].…”

Section: Anti-inlammatory Agentsmentioning

confidence: 99%

Pancreatic Cancer Cachexia: Current Concepts and Clinical Management

Guan¹,

Shinde²,

Hendifar³

2017

Frailty and Sarcopenia - Onset, Development and Clinical Challenges

View full text Add to dashboard Cite

There has been great progress over the last decade in understanding the pathophysiology of cachexia associated with pancreatic cancer. However, there is a large need to ind better therapeutic options to successfully manage this complex and challenging condition. Patients with pancreatic cancer have some of the highest prevalence and often the most severe degrees of cachexia, which is described as a multifactorial metabolic syndrome that is associated with unintended weight loss of adipose tissue and skeletal muscle in the seting of anorexia. This chapter will review the current concepts surrounding pancreatic cancer cachexia, its clinical diagnosis, pathophysiology, and its known and proposed therapeutics. A multimodal approach utilizing nutritional support and pharmaceutical therapies is proposed to lead to the most successful management of pancreatic cancer cachexia.Keywords: pancreatic cancer, cachexia, anorexia, metabolic syndrome, catabolism IntroductionIn western countries, pancreatic cancer represents the fourth leading cause of cancer-related death [1]. Among the many complications associated with this disease, cachexia marked by progressive weight loss represents one of the most distressing features related to pancreatic cancer. Cachexia is a multidimensional wasting syndrome that is characterized by unintended loss of both adipose tissue and lean body mass (LBM) that cannot be fully reversed through conventional nutritional support. It is a complex metabolic disorder frequently described in pancreatic cancer and represents a signiicant physical and psychological burden in approximately 80% of pancreatic cancer patients during the disease progression [2]. The complications © 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. associated with cachexia, which include immobility, impaired immunity, and severe respiratory muscle impairment leading to cardiopulmonary failure, result in death in up to one-third of pancreatic cancer patients [3]. Cachectic patients are observed to have lower physical function, decreased tolerance to chemotherapy and radiation treatment, and generally worse prognosis than those with stable weight. Poorer outcomes after pancreaticoduodenectomy have also been observed in patients with preoperative signs of cachexia [4].While research over the past decade has provided new insights regarding the pathogenesis of pancreatic cancer cachexia, the mechanistic pathology of this condition is still not entirely understood. In this chapter, we will provide a review of the current concepts, potential therapeutic targets, and management of this signiicant clinical condition. Classiication and progression of cancer cachexiaCachexia has been established to be a common adverse efect of cancer. An international consensus in 2011 deined cachexia as a ...

show abstract

“…Furthermore, conjugated DHA with a triene structure has been shown to induce apoptosis in DLD-1 cells (colorectal adenocarcinoma) without any effect on normal human fibroblast cell lines [63]. While there are many examples of co-3 PUFAs-induced apoptosis, at present, the cellular and molecular mechanisms are unclear and a better understanding of the basic actions of (B-3 PUFAs will be needed before these polyunsaturated fatty acids can be fully employed in the clinic as anticancer agents [64,65].…”

Section: Formulation For Smokersmentioning

confidence: 99%

Summer Student Breast Cancer Research Training Program

Zaloga¹,

Spear²

2006

View full text Add to dashboard Cite

The effect of polyunsaturated fatty acids on the progress of cachexia in patients with pancreatic cancer

Cited by 276 publications

References 16 publications

n–3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation

n–3 PUFAs in cancer, surgery, and critical care: a systematic review on clinical effects, incorporation, and washout of oral or enteral compared with parenteral supplementation

Pancreatic Cancer Cachexia: Current Concepts and Clinical Management

Summer Student Breast Cancer Research Training Program

Contact Info

Product

Resources

About